MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 21.03.2026
Immutep Limited Betriebsaufwand 2011-2026 | IMMP
Betriebsaufwand Jährlich Immutep Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | 16.6 M | 16.9 M | 20.5 M | 22.7 M | - |
Alle Zahlen in AUD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 22.7 M | 16.6 M | 19.2 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M |  USA |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Aileron Therapeutics
ALRN
|
65.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
94.5 M | $ 3.34 | -2.91 % | $ 294 M | USA |
 |
Ascendis Pharma A/S
ASND
|
338 M | $ 216.55 | -0.69 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 19.2 | -0.18 % | $ 897 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Kamada Ltd.
KMDA
|
69 K | $ 8.14 | -0.73 % | $ 260 M |  Israel |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.39 | -0.58 % | $ 355 M | Britain |
 |
Kodiak Sciences
KOD
|
277 M | $ 21.26 | -4.41 % | $ 1.11 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
 |
ChemoCentryx
CCXI
|
120 M | - | - | $ 3.74 B | USA |
 |
Aytu BioScience
AYTU
|
53.7 M | $ 2.63 | - | $ 16.5 M | USA |
 |
Atreca
BCEL
|
98.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Karyopharm Therapeutics
KPTI
|
265 M | $ 6.19 | -7.06 % | $ 754 K | USA |
 |
Bellerophon Therapeutics
BLPH
|
22.4 M | - | -74.18 % | $ 955 K | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
52.2 M | $ 4.29 | -2.94 % | $ 822 M | Canada |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Kymera Therapeutics
KYMR
|
389 M | $ 74.44 | -3.27 % | $ 6.29 B | USA |
 |
Calithera Biosciences
CALA
|
125 M | - | -10.95 % | $ 876 K | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
Cara Therapeutics
CARA
|
142 M | - | -3.03 % | $ 260 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Завод ДИОД
DIOD
|
249 M | - | - | - | Russia |